Eltrombopag Combined With Low-dose Rituximab in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies
Status:
Recruiting
Trial end date:
2024-02-28
Target enrollment:
Participant gender:
Summary
This prospective, open-label, nonrandomized, multicenter clinical trial aims at comparing the
efficacy and safety of combined use of eltrombopag with low-dose rituximab vs. the best
available therapy（BAT）in adult immune thrombocytopenia with autoantibodies fail (due to
intolerance or resistance) to first-line treatment.